文献速递冠心病心力衰竭与心肌病心律失常

合成代谢雄激素使用者心血管疾病风险研究

Cardiovascular Disease in Anabolic Androgenic Steroid Users.
PubMed 文献 · Circulation · 2025-02-13

结果显示AAS使用者急性心肌梗死、冠脉血运重建、静脉血栓栓塞、心律失常、心肌病和心力衰竭的发生率显著高于对照。

要点

  • AAS使用者急性心肌梗死风险为对照的3.00倍(aHR 3.00,95%CI 1.67-5.39)。
  • AAS使用者心肌病风险为对照的8.90倍(aHR 8.90,95%CI 4.99-15.88)。
  • AAS使用者心力衰竭、冠脉血运重建、静脉血栓栓塞和心律失常风险也显著增加。

核心结论

  • 在长期随访的大队列中,使用合成代谢雄激素与心血管疾病风险显著增加相关。

研究设计与样本

  • 研究纳入2006-2018年丹麦健身中心因使用AAS被反兴奋剂项目处罚的男性,按年龄和性别与一般丹麦人群对照以1:50匹配,随访至2023年6月30日。

主要发现

  • 平均随访11年,AAS使用者急性心肌梗死发生率显著高于对照(aHR 3.00,95%CI 1.67-5.39)。
  • AAS使用者经皮冠状动脉介入或冠状动脉旁路移植风险显著增加(aHR 2.95,95%CI 1.68-5.18)。
  • AAS使用者静脉血栓栓塞风险显著增加(aHR 2.42,95%CI 1.54-3.80)。
  • AAS使用者心律失常风险显著增加(aHR 2.26,95%CI 1.53-3.32)。
  • AAS使用者心肌病风险显著增加(aHR 8.90,95%CI 4.99-15.88),心力衰竭风险显著增加(aHR 3.63,95%CI 2.01-6.55)。

临床怎么用

  • 对使用合成代谢雄激素的男性应关注心血管疾病风险,包括冠心病、心肌病、心力衰竭、心律失常和静脉血栓栓塞。

局限性

  • AAS使用者中缺血性卒中和心脏骤停病例数有限,这些结局未能报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Use of anabolic androgenic steroids (AASs) is associated with increased mortality, and case reports have suggested that some of these deaths are due to cardiovascular disease. However, the epidemiology of cardiovascular disease in AAS users is still relatively unexplored. This study aimed to measure the incidence of cardiovascular disease in male AAS users and to compare these rates with those of a cohort from the general population matched by age and sex. METHODS: Men sanctioned in an antidoping program for AAS use in Danish fitness centers between 2006 and 2018 were included and matched for age and sex with 50 times as many controls from the general Danish population. The cohort was followed until June 30, 2023. Using the nationwide registries, we obtained information on admissions, prescriptions, educational length, and occupational status for both the AAS users and controls. This study investigated the incidence of acute myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft, venous thromboembolism, ischemic stroke, arrhythmia, cardiomyopathy, heart failure, and cardiac arrest during the follow-up period. RESULTS: During an average of 11 years of follow-up, AAS users (n=1189) demonstrated a significantly higher incidence of several cardiovascular events compared with controls (n=59 450). Correspondingly, AASs were associated with an increased risk of acute myocardial infarction (adjusted hazard ratio [aHR] 3.00 [95% CI, 1.67-5.39]), percutaneous coronary intervention or coronary artery bypass graft (aHR 2.95 [95% CI, 1.68-5.18]), venous thromboembolism (aHR 2.42 [95% CI, 1.54-3.80]), arrhythmias (aHR 2.26 [95% CI, 1.53-3.32]), cardiomyopathy (aHR 8.90 [95% CI, 4.99-15.88]), and heart failure (aHR 3.63 [95% CI, 2.01-6.55]). Due to the limited number of ischemic stroke and cardiac arrest cases among AAS users, these outcomes were not reportable. CONCLUSIONS: AAS use is associated with a substantially increased risk of cardiovascular disease in a large cohort with a long follow-up period.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, et al. Cardiovascular Disease in Anabolic Androgenic Steroid Users. Circulation. 2025. PMID: 39945117. doi:10.1161/CIRCULATIONAHA.124.071117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。